Trial Profile
A randomized phase III trial of postoperative adjuvant oral fluoropyrimidine vs. sequential paclitaxel / oral fluoropyrimidine; and UFT vs. S1 for T3 / T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (SAMIT) Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 May 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary) ; Tegafur/uracil (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAMIT
- 12 May 2021 Results (n=499) assessing a gene signature representing the first predictive biomarker for paclitaxel benefit, published in the Gut.
- 04 Jun 2013 Primary endpoint 'Disease-free-survival' has not been met.
- 04 Jun 2013 Status changed from active, no longer recruiting to completed.